To do this, they used a technique called T cell receptor (TCR) gene therapy. Dr. Christopher Klebanoff is developing new immunotherapy treatments for cancer. In some ways, TCR is similar to chimeric ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the ...

Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery ...

"Super Immune Cells" the Latest Weapon in Battle Against Solid Tumors For more than a decade, cancer has been Judith ...

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key ...

Download your copy now and drive the future of CAR-T and TCR therapies. Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we ...

Immatics N.V., a clinical-stage biopharmaceutical company, announced that it will present data on its lead cell therapy candidate, IMA203 TCR T-cell therapy targeting PRAME, at the upcoming 2025 ...

an engineered T-cell receptor therapy targeting NY-ESO-1 in myxoid/round cell liposarcoma (MRCLS). It is an important step in expanding the use of T-cell–based adoptive cell therapies in different ...

today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual ...